Immunogenicity and Safety of Subunit Plague Vaccine

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

240 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-10-31

Study Completion Date

2015-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Plague is a potentially fatal infection in humans caused by the bacterium Yersinia pestis. Pneumonic plague is typically diagnosed in humans with high mortality. It has a long history for plague as an agent of biowarfare, and poses a serious threat to international security. Althought the killed whole-cell plague vaccine and live attenuated vaccine have been licensed, they are rarely used today because of toxicities, limited evidence for efficacy to prevent plague, and limited commercial availability. In the last twenty years,the recombinant subunit vaccines comprised by fraction 1 capsule(F1)and virulence-associated (V)antigens as the main composition have caused widely attention with providing greater protection than vaccines comprised of either subunit alone. This study was aimed to explor the safety and immunogenicity of a new type plague subunit vaccine which comprised natural F1 antigen and recombined V antigen (F1+rV).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Immunogenicity and Safety of Subunit Vaccine of Plague Vaccine With Two Immunization Regimens

NCT05330624

Plague

UNKNOWN PHASE2

Dose Escalation Trial of a Plague Vaccine, Flagellin/F1/V, in Healthy Adult Volunteers

NCT01381744

Plague

COMPLETED PHASE1

Yersinia Pestis Lateral Flow Immunoassay for Blood Samples

NCT04688996

Plague Plague, Bubonic Plague, Pneumonic +8 more

UNKNOWN

Title: Recombinant Plague Vaccine rF1V in Healthy Volunteers

NCT00332956

Healthy Volunteers

COMPLETED PHASE2

Immune Responses After Human Subject Challenge With Sand Fly Bites

NCT01289977

Healthy

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Plague is a potentially fatal infection in humans caused by the bacterium Yersinia pestis, transmitted naturally from rodent reservoirs to humans via fleas. Human diseases may also result from contact with blood or tissues of infected animals or exposure to aerosolized droplets containing bacteria. Pneumonic plague is typically diagnosed in humans with with high mortality. It has a long history for plague as an agent of biowarfare, and poses a serious threat to international security. In human history, there were three outbreaks of plague all over the world, about 200 million people died from the disease. The increasing trend of plague epidemic in recent years, some regions and countries in the world still have the outbreak of the plague. It implies that safe and effective vaccine is urgently to developing. Althought the killed whole-cell plague vaccine and live attenuated vaccine have been licensed, these vaccines cause significant adverse reactions, including fever, headache, malaise, lymphadenopathy, erythema and induration at the injection site with high degree of immune variability. They are rarely used today because of toxicities, limited evidence for efficacy to prevent plague, and limited commercial availability. Based on the researches in the last twenty years,the recombinant subunit vaccines comprised by fraction 1 capsule(F1)and virulence-associated (V)antigens as the main composition have caused widely attention with providing greater protection than vaccines comprised of either subunit alone. This study was aim to exploring the safety and immunogenicity of a new type plague subunit vaccine which comprised by native F1 antigen and recombined V antigen (F1+rV).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Plague

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

15µg vaccine

15µg plague vaccine of 1.0ml in 120 adults aged 18-55 years old at day 0 and 28.

Group Type EXPERIMENTAL

Plague vaccine

Intervention Type BIOLOGICAL

Plague vaccine is comrised by native fraction 1 capsule (F1) and recombine virulence-associated (V) antigens.

30µg vaccine

30µg plague vaccine of 1.0ml in 120 adults aged 18-55 years old at day 0 and 28.

Group Type EXPERIMENTAL

Plague vaccine

Intervention Type BIOLOGICAL

Plague vaccine is comrised by native fraction 1 capsule (F1) and recombine virulence-associated (V) antigens.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Plague vaccine

Plague vaccine is comrised by native fraction 1 capsule (F1) and recombine virulence-associated (V) antigens.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy adults aged 18-55months old as established by medical history and clinical examination.
* The subjects' guardians are able to understand and sign the informed consent.
* Subjects who can and will comply with the requirements of the protocol.
* Subjects with temperature ≤37.0°C on axillary setting.

Exclusion Criteria

* Family history of seizures or progressive neurological disease.
* Subject who has a medical history of plague, or had been vaccination of plague vaccine.
* Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine.
* Any confirmed or suspected autoimmune diseases or immune deficiency disorders, including human immunodeficiency virus (HIV) infection.
* Dysgenopathy or severe chronic disease.
* Pregnant or lactating women.
* Women of reproductive age without contraception.
* Thrombocytopenia or other blood coagulation disorder, may cause taboo of intramuscular injection.
* Any prior administration of immunodepressant or corticosteroids, and antianaphylactic treatment, cytotoxic therapy in last 6 months.
* Difficult to collecting blood sample.
* Any prior administration of blood products in last 3 month.
* Any prior administration of other research medicines in last 1 month.
* Any prior administration of attenuated live vaccine in last 4 weeks.
* Any prior administration of subunit or inactivated vaccines in last 2 weeks.
* Had fever before vaccination, subjects with temperature \>37.0°C on axillary setting.
* Rash on the injection site that may affect safety observation.
* Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives.

* Any serious adverse events caused by vaccination.
* Hypersensitivity after vaccination (include urticarial or rash in 30 minutes after vaccination).Hypersensitivity after vaccination (include urticarial or rash in 30 minutes after vaccination).
* Other adverse reactions in the opinion of the investigator that affect continue vaccination (include: severely serious symptom of pain, swelling, Limitation of motion, continuous high fever, headache and other Systemic or local reactions).

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes